ArticlePloS one2026
[¹⁸F]PSMA-1007 PET/CT in biochemical recurrence after radical prostatectomy: A single-center experience of detection rate and lesion distribution.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [International journal of urology : official journal of the Japanese Urological Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo define the diagnostic yield and anatomical distribution of [¹⁸F]prostate-specific membrane antigen (PSMA)-1007 positron emission tomography/computed tomography (PET/CT) in post-radical-prostatectomy biochemical recurrence (BCR) and to establish prostate-specific antigen (PSA)-stratified performance benchmarks, independent predictors of PET positivity, and clinical utility for PSMA-guided metastasis-directed therapy.
methodsA single-centre retrospective cohort of 245 consecutive BCR patients (PSA ≥ 0.2 ng/mL) who underwent uniform [¹⁸F]PSMA-1007 PET/CT (90 ± 10 min post-injection; molar activity > 30 GBq µmol⁻¹) between June 2022 and November 2025 was analysed. Detection rates were correlated with PSA strata, and independent predictors of PET positivity were identified via multivariable logistic regression. Lesion location was verified by histology, targeted therapy response, or unequivocal imaging follow-up. Inter-observer agreement for image interpretation was quantified using Cohen's kappa.
resultsAt median PSA 0.9 ng/mL (interquartile range 0.5-2.1), 184/245 patients (75.1%, 95% CI: 69.3-80.3%) exhibited ≥ 1 [¹⁸F]PSMA-1007-avid lesion. Detection rates increased with PSA: 56.5% (0.2-0.5 ng/mL) to 90.5% (≥ 1.5 ng/mL). Independent predictors of PET positivity were serum PSA (OR = 2.87), ISUP grade (OR = 1.63), and PSA doubling time (OR = 0.72) (all P < 0.01). In 132 verified cases, a "pelvic-first" pattern was observed: isolated prostatic fossa (34.8%), isolated nodal (38.6%), isolated osseous (20.4%), and multi-region disease (6.1%). Median SUVmax was comparable across lesion types (≈ 17.5; P = 0.63), with excellent inter-observer agreement (Cohen's κ = 0.86 for positivity, 0.82 for localization; both P < 0.001).
conclusion[¹⁸F]PSMA-1007 PET/CT delivers high, PSA-dependent detection efficiency even at PSA < 0.5 ng/mL, with excellent inter-observer reliability. Serum PSA, ISUP grade, and PSA doubling time independently predict PET positivity, and the modality accurately maps predominantly pelvic, oligometastatic recurrences suitable for focal salvage therapy. These data support its utility as a first-line imaging tool for post-prostatectomy BCR staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.